Abstract
Purpose: Multiple myeloma is a malignant plasma cell disorder accounting for about 10% of hematological malignancies. Despite treatment advances, including hematopoietic stem-cell transplantation to facilitate administration of high-dose cytotoxic chemotherapy, the median survival remains
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have